Phase II, multicenter, open-label, non-randomized study of neoadjuvant chemotherapy NALIRINOX (5-FU/LV + oxaliplatin + nal-IRI) followed by chemoradiotherapy in patients with rectal cancer in a watch-and-wait program.doi:10.1200/JCO.2022.40.16_suppl.3612...
public DocumentFormat.OpenXml.StringValue? GetVisible { get; set; } Property Value StringValue Applies to ProduktsVersijas DocumentFormat.OpenXml 2.7.1, 2.7.2, 2.8.0, 2.8.1, 2.9.0, 2.9.1, 2.10.0, 2.10.1, 2.11.0, 2.11.1, 2.11.2, 2.11.3, 2.12.0, 2.12.1, 2.12.2, 2.12.3,...
SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancerdoi:10.1016/j.annonc.2020.08.459V. Boni...
FINAL RESULTS OF OPEN-LABEL, DOSE CONFIRMATION STUDY OF INTERSTITIAL COTARA (I-131-chTNT-1/b MAb) FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) AT FIRST RELAPSEShapiro, WilliamGopal, SwaroopJudy, KevinPatel, SunilMahapatra, AshokShan, Joseph...